Literature DB >> 27297086

Study on the expression of PAK4 and P54 protein in breast cancer.

Yanqing Bi1, Mengzi Tian1, Jinghong Le2, Linlin Wang3, Xiaofang Liu1, Jianhua Qu1, Min Hao4.   

Abstract

BACKGROUND: Previous evidence have demonstrated that p21-activated kinase PAK4 was correlated with breast cancer. The aim of this paper is to study the expression and interaction of p21-activated kinase (pAK)-4 and P54 protein in breast cancer.
METHODS: A total of 80 patients were enrolled in our study (breast fibroma n = 20, breast noninvasive cancer n = 20, early breast invasive cancer n = 20, and advanced breast invasive cancer). The expression of PAK4 was detected by immunohistochemical S-P method, and the relationship between them and the different pathological characteristics were compared. The subcellular localization of P54 and PAK4 in vitro was observed by immunofluorescence assay.
RESULTS: The expression of both PAK4 and P54 in breast cancer was much higher than that in breast fibroma. Meanwhile, we found that both PAK4 and P54 increased gradually as breast cancer progressed (advanced invasive > early invasive > noninvasive). The positive staining of P54 were mainly located in the cytoplasm, especially around the nucleus. There was no significant stained region in the cell matrix. The P54 localization in the cytoplasm was verified by confocal experiment, and the PAK4 was co-localized.
CONCLUSIONS: PAK4 and P54 proteins may be used as molecular markers for diagnosis and treatment of breast cancer.

Entities:  

Keywords:  Breast cancer; P54; PAK4

Mesh:

Substances:

Year:  2016        PMID: 27297086      PMCID: PMC4906770          DOI: 10.1186/s12957-016-0913-6

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


Background

Breast cancer ranks the first among women malignant tumors, accounting for 7 to 10 % of the whole body cancer. Peripheral blood tumor marker detection is an important measure for early diagnosis of breast cancer. CA125, CEA, and TPS are the present common serum tumor markers. HER-2/Neu, estrogen receptor (ER), progesterone receptor (PR), epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and vascular endothelial growth factor (VEGF) are detected by pathological specimens. The positive rate and positive predictive value are not that satisfactory and are often used as reference index for clinical diagnosis and treatment. Along with advancement of scientific research, the pathways for phosphorylation/de-phosphorylation of proteins are found to be important for signal transduction, and their balance has a crucial role in the cell’s normal signal transduction and tumor occurrence or development. There have been some studies that p21-activated kinase (pAK)-4 has a high expression in breast cancer and ovarian cancer [1-3]. The purpose of our study was to explore the expression of PAK4 and P54 in breast cancer and the correlation of these proteins with pathological stages of breast cancer.

Methods

Clinical specimens

A total of 80 patients from April 2013 to April 2015 were enrolled in our study (breast fibroma n = 20, breast noninvasive cancer n = 20, early breast invasive cancer n = 20, and advanced breast invasive cancer). The ages of patients with breast fibroma ranged from 30 to 72 years with a mean value of 44.5 ± 16.3 years. And the ages of patients with breast noninvasive cancer ranged from 29 to 66 years with a mean value of 42.5 ± 10.3 years. Among them, there were five ER-positive cases, four PR-positive cases, and three double-positive cases. The ages of patients with early breast invasive cancer ranged from 32 to 73 years with a mean value of 45.6 ± 14.2 years. Among them, there were four ER-positive cases, five PR-positive cases, and five double-positive cases. The ages of patients with advanced breast invasive cancer ranged from 46 to 77 years with a mean value of 52.3 ± 16.7 years. Among them, there were six ER-positive cases, four PR-positive cases, and four double-positive cases. All the patients were treated for the first time without drug treatment, surgical resection, chemotherapy history, severe heart, liver, kidney, other organ dysfunction, or other malignant tumors, etc. For the study, we obtained the consent of the patients and their families, and this study was approved by the ethics committee of our hospital. For the same tissue, specimens were obtained from three different loci and completed by the same experienced expert, and the specimens were all fixed by 10 % formalin and embedded in paraffin with 4-μm continuous slicing.

Immunohistochemistry S-P method

Main reagents and equipment

For this study, we used the following: rabbit IgG (Nanjing Kaiji Company) and peroxidase-labeled goat anti-rabbit IgG (Shenzhen Jinmei Biological Co., Ltd.), antibody dilutions (Wuhan Boshide Biotechnology Company), constitutive rafter acid salt buffer liquid powder (Nanjing Kaiji Company), and neutral gum (Shanghai Specimen Model Factory). Paraffin sections made from a tissue-slicing machine (Leica, Germany) were dewaxed in water; 3 % H2O2 was incubated at room temperature for 5 ~ 10 min, to eliminate endogenous peroxidase activity. The S-P immunohistochemical reagent kit was provided by Fujian Maixin Biotechnology Company.

Procedure

The sections on the slides were rinsed three times in water and PBS, to keep the antigen intact (Shanghai Fengxian Shenxin Chemical Factory). After rinsing with PBS three times, goat serum (Guangzhou Jietewei Company) was flooded on sections for 20 min at room temperature. Subsequently, the first 50 μl of rabbit anti-human PAK4 polyclonal antibody (l: 200 dilution) (Germany BioGenes GmbH) was added to the sections and incubated at 37 °C for 1 ~ 2 h, followed by incubation at 4 °C overnight. The next day, the slides were washed with PBS at 37 °C for 45 min, rinsed three times with PBS. Next, biotin-labeled sheep anti-rabbit IgG antibody was added to sections at 37 °C and incubated for 10 to 30 min. It was followed by three times PBS washing, then HRP streptavidin solution was added and the slides were incubated at 37 °C for 10 to 30 min. The slides were rinsed with PBS three times, and DAB solution (Guangzhou Jietewei Company) was added for 5 ~ 10 min, followed by PBS wash for 10 min. Finally, the sections were counterstained with hematoxylin staining for 2 min, hydrochloric acid alcohol was differentiated, and ammonia turned back to blue. In the next step, the sections were washed with tap water for 10 ~ 15 min, dehydrated and transparent, and mounted for microscopic examination (OLYMPUS BX-4O optical microscope, Olympus, Japan).

Scoring for stained sections

For interpretation of results, the Standard of Campo was followed (3). No color was given 0 points, weak color 1 point, moderate color 2 points, and strong color 3 points. Stained cells accounted for the total number of cells were less than 5 % for 0 points, 5 ~ 25 % for 1 point, 26 ~ 50 % for 2 points, and more than 51 % for 3 points. Finally, the results were determined by the total score of the percentage of positive cells and the staining intensity score: 0 points for negative, 1 to 2 points for weak positive, 3 to 4 points for medium positive, and more than 5 points for the strong positive. The results of the test were double blind-determined by two pathologists based on the same criteria. The different results were double blind-determined by another pathologist, and the mean value of the three persons was included in the statistics.

Immunofluorescence

The cells were placed on a 12-hole cell culture plate, until the cells adhere to start expressing P54 and PAK4 protein plasmid; a double free DMEM was added to incubate for 4 h, which was later replaced with a DMEM culture medium, and the cells were cultured for 24 h, to guarantee outward plasmid normal protein expression. After 24 h, the culture medium was discarded and washed three times with PBS. The PBS was discarded, and the cells were fixed with 700 μl of 4 % paraform for 10 min. After three times washing with PBS, 0.1 % Triton-X-100 was added to permeabilize the cell at room temperature for 10 min. Next, again the slides were rinsed with PBS three times, followed by addition of 1 % sheep serum at room temperature for 1 h. Subsequently, the slides were incubated with the anti-PAK4 (1:2000) and anti-myc (1:2000) antibody at room temperature for 1 h and washed with PBS three times. Subsequently, Alexa-546 red mark goat anti-mouse antibody (1:5000) was added to incubate for l h in dark, followed by washing with PBS three times. Topro-3 nuclear staining was performed for 30 min and later washed with PBS three times. Finally, 50 % glycerol was added to the slides for mounting, to observe the subcellular localization of proteins in confocal laser scanning microscopy.

Statistical analysis

SPSS20.0 software (SPSS Chicago, Ill) was used for the statistical analysis. All quantitative data were expressed as mean ± standard deviation. Comparison between groups was done using one-way ANOVA test followed by a post hoc test (LSD). Percentage (%) was used to express the enumeration data, and a chi-squared test was used for data analysis. The nonparametric total rank of independent samples of grade data was used to test. p values <0.05 were considered statistically significant

Results

Expression of PAK4 protein in different breast tissues

Expression of PAK4 in breast cancer was much higher than that in breast fibroma, and we found that PAK4 increased gradually as breast cancer progressed (advanced invasive > early invasive > noninvasive). The positive products were mainly located in the cytoplasm, especially obvious around the nucleus, and there was no significant dyeing in the cell matrix (p < 0.05) (Table 1, Fig. 1).
Table 1

Expression of PAK4 in different breast tissues

GroupNo. of casesNegativeWeakly positiveModerately positiveStrong positiveKruskal-Wallis p value
Normal tissue201550015.623<0.001
Fibroma2010730
Metastatic tumor tissue206842
Breast cancer201289
Fig. 1

Expression of PAK4 protein in different breast tissues detected by immunohistochemistry. a Normal tissue. b Fibroma. c Metastatic tumor tissue. d Breast cancer

Expression of PAK4 in different breast tissues Expression of PAK4 protein in different breast tissues detected by immunohistochemistry. a Normal tissue. b Fibroma. c Metastatic tumor tissue. d Breast cancer

Expression of PAK4 protein in different pathological types

Expression of P54 in breast cancer was much higher than that in breast fibroma, and we found that P54 increased gradually as breast cancer progressed (advanced invasive > early invasive > noninvasive). The differences were all statistically significant (p < 0.05) (Table 2).
Table 2

Expression of PAK4 in different pathological types

Pathological typeNo. of casesNegativeWeakly positiveModerately positiveStrong positiveKruskal-Wallis p value
Noninvasive carcinoma4111112.432<0.001
Early invasive carcinoma60132
Advanced invasive carcinoma100046
Expression of PAK4 in different pathological types

Cellular localization of P54 and PAK4 proteins

P54 localization in the cytoplasm was verified by confocal experiment, and the PAK4 was co-localized as shown in Figs. 2 and 3. Expression of both PAK4 and P54 in breast cancer was much higher than that in breast fibroma and increased gradually as breast cancer progressed (advanced invasive 32.6 ± 8.2 % > early invasive 12.4 ± 3.5 % > noninvasive 2.0 ± 0.5 % > breast fibroma 0.2 ± 0.1 %; F = 20.325, p < 0.001).
Fig. 2

Subcellular localization of GFP-P54 protein. a Green GFP-p54. b Blue Topro3. c Merged

Fig. 3

Cellular co-localization of GFP-P54 protein and PAK4 protein. a Green GFP-p54. b Red His-PAK4. c Blue Topro3. d Merged

Subcellular localization of GFP-P54 protein. a Green GFP-p54. b Blue Topro3. c Merged Cellular co-localization of GFP-P54 protein and PAK4 protein. a Green GFP-p54. b Red His-PAK4. c Blue Topro3. d Merged

Discussion

PAK, P21 small GTP-activated kinase, is a serine/threonine protein kinase family. The molecular weight of 21kD, small GTP enzyme of Rho family, Cdc42, and Racl are the upstream molecules of PAKS, in the molecular structure; the end of N PAK is the regulation region of the kinase; the end of C is the substrate binding region with kinase activity [4]. PAK4 is a member of the PAK family, which is closely related to human tumor. It plays an important role in the repair of the cytoskeleton, the life of the normal cells, the positive regulation of some normal physiological metabolism, etc. [5-9]. In our study, expression of PAK4 in breast cancer was much higher than that in breast fibroma and increased gradually as breast cancer progressed (advanced invasive > early invasive > noninvasive). The positive products were mainly located in the cytoplasm, around the nucleus, as there was no significant staining in the cell matrix. The positive rate of PAK4 expression in noninvasive carcinoma, early invasive carcinoma, and advanced invasive carcinoma increased gradually, and the differences were all statistically significant. It shows that PAK4 may be used as a sensitive indicator and has important significance in judging the malignant degree and pathological types of breast cancer. There is some research by constructing PAK4 eukaryotic expression vector and PAK4 ShRNA eukaryotic expression vector, transfecting breast cancer MDA-MB-231 cells, which showed that after up-regulation of PAK4 expression in breast cancer cells, it can significantly promote breast cancer cell proliferation; inhibit apoptosis; increase cell adhesion, movement, invasion, tumorigenesis, and other biological activity; and vice versa [10]. The normal mammary gland epithelium has active cell proliferation and cell apoptosis; in normal circumstances, there is a dynamic balance between cell proliferation and cell apoptosis, which is the main mechanism of breast mucosal removal of damaged cells [11, 12]. PAKs family plays an important role in the process of cell repair. Studies have shown that PAK4 is regulated by growth factors [13]. P54 protein is a kind of neuron-specific protein, and it is an effective microtubule instability factor and membrane-associated protein. P54 protein has a certain relationship with tumor, and P54 provides a new basis for the further improvement of PAK4 tumor signaling pathway [14, 15]. P54 as a member of the family has a structure of three functional regions: the membrane-binding region of the N end, the central regulatory region, and the coiled coil region of the C end. In the center of regulation of phosphorylation sites, there are phosphorylation sites of MAP and PKA kinase, and these phosphorylation sites can regulate microtubule depolymerization [16, 17]. Our study showed that the expression of P54 in breast cancer was much higher than that in breast fibroma and increased gradually as breast cancer progressed (advanced invasive > early invasive > noninvasive). We also found that P54 is located in the cytoplasm with PAK4 co-located. Two hybrid experiments have been shown through yeast, screen-interacting protein P54 and PAK4, and they were transferred to the AH109 yeast strain for yeast verification [18]. The results showed that both could interact; GST pull-down assay results further confirmed the interaction in vitro, and immune precipitation experiment verified the interaction in vivo. In summary, AK4 and P54 proteins may be used as molecular markers for diagnosis and treatment of breast cancer.

Conclusions

PAK4 expression in breast cancer is adjacent normal tissues, breast fibroma, and breast cancer metastasis tissues, and breast cancer increased gradually. The positive staining was mainly located in the cytoplasm, especially more obvious around the nucleus. Besides, the positive rate of PAK4 expression in noninvasive carcinoma, early invasive carcinoma, and advanced invasive carcinoma also increased gradually. The P54 localization in the cytoplasm and the PAK4 was co-localized, so that PAK4 and P54 proteins may be used as molecular markers for diagnosis and treatment of breast cancer.
  18 in total

1.  Xenopus p21-activated kinase 5 regulates blastomeres' adhesive properties during convergent extension movements.

Authors:  Sandrine Faure; Julien Cau; Pascal de Santa Barbara; Stéphanie Bigou; Qingyuan Ge; Claude Delsert; Nathalie Morin
Journal:  Dev Biol       Date:  2005-01-15       Impact factor: 3.582

2.  Systems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by quantitative phosphoproteomics.

Authors:  Florian Gnad; Amy Young; Wei Zhou; Karen Lyle; Christy C Ong; Matthew P Stokes; Jeffrey C Silva; Marcia Belvin; Lori S Friedman; Hartmut Koeppen; Audrey Minden; Klaus P Hoeflich
Journal:  Mol Cell Proteomics       Date:  2013-04-22       Impact factor: 5.911

Review 3.  PAK signalling during the development and progression of cancer.

Authors:  Maria Radu; Galina Semenova; Rachelle Kosoff; Jonathan Chernoff
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

4.  Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions.

Authors:  Zhibo Yang; Suresh Rayala; Diep Nguyen; Ratna K Vadlamudi; Shiuan Chen; Rakesh Kumar
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

5.  p54(nrb)/NONO regulates lipid metabolism and breast cancer growth through SREBP-1A.

Authors:  Z Zhu; X Zhao; L Zhao; H Yang; L Liu; J Li; J Wu; F Yang; G Huang; J Liu
Journal:  Oncogene       Date:  2015-07-06       Impact factor: 9.867

6.  Inhibitors of p21-activated kinases (PAKs).

Authors:  Joachim Rudolph; James J Crawford; Klaus P Hoeflich; Weiru Wang
Journal:  J Med Chem       Date:  2014-12-03       Impact factor: 7.446

7.  Nuclear localization and chromatin targets of p21-activated kinase 1.

Authors:  Rajesh R Singh; Chunying Song; Zhibo Yang; Rakesh Kumar
Journal:  J Biol Chem       Date:  2005-03-03       Impact factor: 5.157

8.  Immunodetection of nmt55/p54nrb isoforms in human breast cancer.

Authors:  M Pavao; Y H Huang; L J Hafer; R B Moreland; A M Traish
Journal:  BMC Cancer       Date:  2001-10-29       Impact factor: 4.430

9.  The Cdc42 Effector Kinase PAK4 Localizes to Cell-Cell Junctions and Contributes to Establishing Cell Polarity.

Authors:  Widyawilis Selamat; Pei-Ling Felicia Tay; Yohendran Baskaran; Ed Manser
Journal:  PLoS One       Date:  2015-06-11       Impact factor: 3.240

10.  Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.

Authors:  Christy C Ong; Sarah Gierke; Cameron Pitt; Meredith Sagolla; Christine K Cheng; Wei Zhou; Adrian M Jubb; Laura Strickland; Maike Schmidt; Sergio G Duron; David A Campbell; Wei Zheng; Seameen Dehdashti; Min Shen; Nora Yang; Mark L Behnke; Wenwei Huang; John C McKew; Jonathan Chernoff; William F Forrest; Peter M Haverty; Suet-Feung Chin; Emad A Rakha; Andrew R Green; Ian O Ellis; Carlos Caldas; Thomas O'Brien; Lori S Friedman; Hartmut Koeppen; Joachim Rudolph; Klaus P Hoeflich
Journal:  Breast Cancer Res       Date:  2015-04-23       Impact factor: 6.466

View more
  11 in total

Review 1.  The significance of PAK4 in signaling and clinicopathology: A review.

Authors:  Xinbo Yu; Changwei Huang; Jiyuan Liu; Xinyu Shi; Xiaodong Li
Journal:  Open Life Sci       Date:  2022-06-20       Impact factor: 1.311

2.  hsa-miR-199a-3p Inhibits Motility, Invasiveness, and Contractility of Ovarian Endometriotic Stromal Cells.

Authors:  Ruofei Zhu; Kaei Nasu; Naoki Hijiya; Masato Yoshihashi; Tomoko Hirakawa; Yoko Aoyagi; Hisashi Narahara
Journal:  Reprod Sci       Date:  2021-05-13       Impact factor: 3.060

3.  KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.

Authors:  Emma Cordover; Janet Wei; Chadni Patel; Naing Lin Shan; John Gionco; Davit Sargsyan; Renyi Wu; Li Cai; Ah-Ng Kong; Estela Jacinto; Audrey Minden
Journal:  Chem Res Toxicol       Date:  2020-01-09       Impact factor: 3.973

4.  The Effect of Functional Mandibular Shift on the Muscle Spindle Systems in Head-Neck Muscles and the Related Neurotransmitter Histamine.

Authors:  Bing-Li Du; Jiang-Ning Li; Hong-Ming Guo; Song Li; Biao Liu
Journal:  J Craniofac Surg       Date:  2017-09       Impact factor: 1.046

5.  A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.

Authors:  Chetan Rane; William Senapedis; Erkan Baloglu; Yosef Landesman; Marsha Crochiere; Soumyasri Das-Gupta; Audrey Minden
Journal:  Sci Rep       Date:  2017-02-15       Impact factor: 4.379

6.  LINC01088 inhibits tumorigenesis of ovarian epithelial cells by targeting miR-24-1-5p.

Authors:  Weijiang Zhang; Jing Fei; Shuqian Yu; Jiayu Shen; Xiaoqing Zhu; Annapurna Sadhukhan; Weiguo Lu; Jianwei Zhou
Journal:  Sci Rep       Date:  2018-02-13       Impact factor: 4.379

Review 7.  NONO and tumorigenesis: More than splicing.

Authors:  Peifu Feng; Ling Li; Tanggang Deng; Yan Liu; Neng Ling; Siyuan Qiu; Lin Zhang; Bo Peng; Wei Xiong; Lanqin Cao; Lei Zhang; Mao Ye
Journal:  J Cell Mol Med       Date:  2020-03-13       Impact factor: 5.310

8.  PAK4 inhibition improves PD-1 blockade immunotherapy.

Authors:  Catherine S Grasso; Antoni Ribas; Gabriel Abril-Rodriguez; Davis Y Torrejon; Wei Liu; Jesse M Zaretsky; Theodore S Nowicki; Jennifer Tsoi; Cristina Puig-Saus; Ignacio Baselga-Carretero; Egmidio Medina; Michael J Quist; Alejandro J Garcia; William Senapedis; Erkan Baloglu; Anusha Kalbasi; Gardenia Cheung-Lau; Beata Berent-Maoz; Begoña Comin-Anduix; Siwen Hu-Lieskovan; Cun-Yu Wang
Journal:  Nat Cancer       Date:  2019-12-09

9.  PAK4 phosphorylating RUNX1 promotes ERα-positive breast cancer-induced osteolytic bone destruction.

Authors:  Lina Tang; Yunling Gao; Yongqi Song; Yang Li; Yanshu Li; Hongyan Zhang; Danni Li; Jiabin Li; Caigang Liu; Feng Li
Journal:  Int J Biol Sci       Date:  2020-05-25       Impact factor: 6.580

10.  Effects of PAK4/LIMK1/Cofilin-1 signaling pathway on proliferation, invasion, and migration of human osteosarcoma cells.

Authors:  Zhi-Feng Li; Yin-Di Yao; Yin-Yin Zhao; Yan Liu; Zhen-Hua Liu; Pei Hu; Zhuo-Ran Zhu
Journal:  J Clin Lab Anal       Date:  2020-05-28       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.